The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
CEA is expressed by more than 90% of colorectal cancers, as well
as by a large number of other carcinomas, including esophageal,
stomach, lung, breast, pancreas, uterus, and ovarian cancer. It has
been shown that this tumor marker can serve as a useful target for
radiolabeled antibodies. Since CEA-Scan uses a small antibody
fragment at a low dose, there is virtually no immune reaction by
subjects to the foreign protein. In addition, linking the fragment
with technetium-99m, a common radioisotope in nuclear medicine,
permits tumor detection within a few hours, using conventional
Mechanism of Action
CEA-Scan comprises an antibody fragment (Fab') against the
tumor marker, carcinoembryonic antigen ("CEA").
Each year there are approximately 134,000 new cases of
colorectal cancer in the United States; colorectal cancer is
estimated to kill over 55,000 Americans annually. Trials are also
under way for lung and breast cancer indications.